Citations

Showing 10 of 108152 citations.

Should high risk smoldering myeloma be treated outside a clinical trial: NO
Gertz, Morie A. , Gertz, Morie A , Vaxman, Iuliana

Mayo Clinic

Leukemia & Lymphoma | July 14, 2021 | Volume: 62 | Issue: 11 | Pages: 2565-2567

10.1080/10428194.2021.1951723 | PMID 34261405 Get It

Electrical Brain Stimulation for Epilepsy and Emerging Applications
Worrell, Gregory A.

Mayo Clinic

Journal of Clinical Neurophysiology | July 14, 2021 | Volume: 38 | Issue: 6 | Pages: 471-477

10.1097/wnp.0000000000000819 | PMID 34261111 Get It

Summary: Electrical brain stimulation is an established therapy for movement disorders, epilepsy, obsessive compulsive disorder, and a potential therapy for many other neurologic and psychiatric disorders. Despite significant progress and FDA approvals, there remain significant clinical gaps that can be addressed with next generation systems. Integrating wearable sensors and implantable brain devices with off-the-body computing resources (smart phones and cloud resources) opens a new vista for dense behavioral and physiological signal tracking coupled with adaptive stimulation therapy that should have applications for a range of brain and mind disorders. Here, we briefly review some history and current electrical brain stimulation applications for epilepsy, deep brain stimulation and responsive neurostimulation, and emerging applications for next generation devices and systems.
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1
Chawla, Sant P., Tine, Brian A. Van , Pollack, Seth M., Ganjoo, Kristen N., Elias, Anthony , Riedel, Richard F. , Attia, Steven, Choy, Edwin , Okuno, Scott H., Agulnik, Mark , Livingston, Michael B., Keedy, Vicki L. , Philip, Tony , Bohac, G. Chet, Yurasov, Sergey , Yakovich, Adam, Lu, Hailing , Chen, Michael, Maki, Robert G. , Van Tine, Brian A , Elias, Anthony D , von Mehren, Margaret , Keedy, Vicki L , Verschraegen, Claire F , Philip, Tony , Yurasov, Sergey , Lu, Hailing , Maki, Robert G , Choy, Edwin , Riedel, Richard F , Chawla, Sant P., Pollack, Seth M., Ganjoo, Kristen N., Attia, Steven, Okuno, Scott H., Agulnik, Mark , Livingston, Michael B., Bohac, G. Chet, Yakovich, Adam, Chen, Michael

Mayo Clinic

Journal of Clinical Oncology | July 14, 2021 | Volume: 40 | Issue: 12 | Pages: 1291-1300

10.1200/jco.20.03452 | PMID 34260265 Get It

PURPOSE CMB305 is a heterologous prime-boost vaccination regimen created to prime NY-ESO-1–specific CD8 T-cell populations and then activate the immune response with a potent TLR-4 agonist. This open-label randomized phase II trial was designed to investigate the efficacy and safety of adding the CMB305 regimen to atezolizumab (anti–programmed death ligand-1 therapy) in comparison with atezolizumab alone in patients with synovial sarcoma or myxoid liposarcoma. PATIENTS AND METHODS Patients with locally advanced, relapsed, or metastatic synovial sarcoma or myxoid liposarcoma (any grade) were randomly assigned to receive CMB305 with atezolizumab (experimental arm) or atezolizumab alone (control arm). The primary end points were progression-free survival (PFS) and overall survival (OS) analyzed using the Kaplan-Meier method. Safety and immune responses were assessed. RESULTS A total of 89 patients were enrolled; 55.1% had received ≥ 2 prior lines of chemotherapy. Median PFS was 2.6 months and 1.6 months in the combination and control arms, respectively (hazard ratio, 0.9; 95% CI, 0.6 to 1.3). Median OS was 18 months in both treatment arms. Patients treated with combination therapy had a significantly higher rate of treatment-induced NY-ESO-1–specific T cells ( P = .01) and NY-ESO-1–specific antibody responses ( P < .0001). In a post hoc analysis of all dosed patients, OS was longer (36 months) in the subset who developed anti-NY-ESO-1 T-cell immune response (hazard ratio, 0.3; P = .02). CONCLUSION Although the combination of CMB305 and atezolizumab did not result in significant increases in PFS or OS compared with atezolizumab alone, some patients demonstrated evidence of an anti-NY-ESO-1 immune response and appeared to fare better by imaging than those without such an immune response. Combining prime-boost vaccines such as CMB305 with anti–programmed death ligand-1 therapies merits further evaluation in other clinical contexts.
Considerations from the College of American Pathologists for Implementation of an Assay for SARS-CoV-2 Testing after a Change in Regulatory Status
Peaper, David R. , Rhoads, Daniel D. , Sullivan, Kaede V. , Couturier, Marc Roger , Humphries, Romney M. , Nolte, Frederick S. , Rowlinson, Marie‐Claire , She, Rosemary C. , Simner, Patricia J. , Theel, Elitza S. , Wojewoda, Christina , Nolte, Frederick S , Simner, Patricia J , Theel, Elitza S , Wojewoda, Christina M , Humphries, Romney , Rhoads, Daniel D , Martin, Isabella W.

Mayo Clinic

Journal of Clinical Microbiology | July 14, 2021 | Volume: 59 | Issue: 10 | Pages: No page available

10.1128/jcm.01167-21 | PMID 34260276 Get It

The U.S. Food & Drug Administration (FDA) regulates the marketing of manufacturers’ in vitro diagnostic tests (IVDs), including assays for the detection of SARS-CoV-2.
Prognostic value of stress echocardiography assessed by the ABCDE protocol
Zagatina, A , Cortigiani, Lauro , Wierzbowska‐Drabik, Karina , Kasprzak, Jarosław D. , Djordjevic‐Dikic, Ana , Boshchenko, A , Ryabova, T. R. , Gaibazzi, Nicola , Rigo, Fausto , Dodi, Claudio , Simova, Iana , Samardjieva, Martina, Barbieri, Andréa , Lorenzoni, Valentina , Prota, Costantina , Villari, Bruno, Antonini‐Canterin, Francesco, Carpeggiani, Clara , Pellikka, Patricia A. , Picano, Eugenio , Zagatina, Angela , Cortigiani, Lauro , Wierzbowska-Drabik, Karina , Kasprzak, Jaroslaw D , Ryabova, Tamara , Gaibazzi, Nicola , Barbieri, Andrea , Lorenzoni, Valentina , Prota, Costantina , Pepi, Mauro , Carpeggiani, Clara , Pellikka, Patricia A , Picano, Eugenio , Boshchenko, Alla , Ciampi, Quirino , Haberka, Maciej , Beleslin, Branko , Morrone, Doralisa

Mayo Clinic

European Heart Journal | July 14, 2021 | Volume: 42 | Issue: 37 | Pages: 3869-3878

10.1093/eurheartj/ehab493 | PMID 34449837 Get It

Abstract Aim The aim of this study was to assess the prognostic value of ABCDE-SE in a prospective, large scale, multicentre, international, effectiveness study. Stress echocardiography (SE) was recently upgraded to the ABCDE protocol: step A, regional wall motion abnormalities; step B, B lines; step C, left ventricular contractile reserve; step D, Doppler-based coronary flow velocity reserve in left anterior descending coronary artery; and step E, electrocardiogram-based heart rate reserve. Methods and results From July 2016 to November 2020, we enrolled 3574 all-comers (age 65 ± 11 years, 2070 males, 58%; ejection fraction 60 ± 10%) with known or suspected chronic coronary syndromes referred from 13 certified laboratories. All patients underwent clinically indicated ABCDE-SE. The employed stress modality was exercise (n = 952, with semi-supine bike, n = 887, or treadmill, n = 65 with adenosine for step D) or pharmacological stress (n = 2622, with vasodilator, n = 2151; or dobutamine, n = 471). SE response ranged from score 0 (all steps normal) to score 5 (all steps abnormal). All-cause death was the only endpoint. Rate of abnormal results was 16% for A, 30% for B, 36% for C, 28% for D, and 37% for E steps. During a median follow-up of 21 months (interquartile range: 13–36), 73 deaths occurred. Global X 2 was 49.5 considering clinical variables, 50.7 after step A only (P = NS (not significant)) and 80.6 after B–E steps (P &lt; 0.001 vs. step A). Annual mortality rate ranged from 0.4% person-year for score 0 up to 2.7% person-year for score 5. Conclusion ABCDE-SE allows an effective prediction of survival in patients with chronic coronary syndromes.
CT radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment
Vincent, Phuong , Maeder, Matthew E., Linn, Bryan, Mangels-Dick, Tiffany, Hasan, Tayyaba , Wang, Kenneth K, Hasan, Tayyaba , Hunt, Brady , Pogue, Brian W.

Mayo Clinic

Physics in Medicine & Biology | July 14, 2021 | Volume: 66 | Issue: 17 | Pages: 175006

10.1088/1361-6560/ac1458 | PMID 34261044 Get It

Abstract Photodynamic therapy (PDT) offers localized focal ablation in unresectable pancreatic tumors while tissues surrounding the treatment volume experience a lower light dose, termed photodynamic priming (PDP). While PDP does not cause tissue damage, it has been demonstrated to promote vascular permeability, improve drug delivery, alleviate tumor cell density, and reduce desmoplasia and the resultant internal pressure in pre-clinical evaluation. Preclinical data supports PDP as a neoadjuvant therapy beneficial to subsequent chemotherapy or immunotherapy, yet it is challenging to quantify PDP effects in clinical treatment without additional imaging and testing. This study investigated the potential of radiomic analysis using CT scans acquired before and after PDT to identify areas experiencing PDT-induced necrosis as well as quantify PDP effects in the surrounding tissues. A total of 235 CT tumor slices from seven patients undergoing PDT for pancreatic tumors were examined. Radiomic features assessed included intensity metrics (CT number in Hounsfield Units) and texture analysis using several gray-level co-occurrence matrix (GLCM) parameters. Pre-treatment scans of tumor areas that resulted in PDT-induced necrosis showed statistically significant differences in intensity and texture-based features that could be used to predict the regions that did respond (paired t-test, response versus no response, p < 0.001). Evaluation of PDP effects on the surrounding tissues also demonstrated statistically significant differences, in tumor mean value, standard deviation, and GLCM parameters of contrast, dissimilarity and homogeneity (t-test, pre versus post, p < 0.001). Using leave-one-out cross validation, six intensity and texture-based features were combined into a support-vector machine model which demonstrated reliable prediction of treatment effects for six out of seven patients (ROC curve, AUC = 0.93). This study provides pilot evidence that texture features extracted from CT scans could be utilized as an effective clinical diagnostic prediction and assessment of PDT and PDP effects in pancreatic tumors. (clinical trial NCT03033225)
Gait synchronized neuromuscular electrical stimulation to the gluteus medius on a patient with right hemiparesis: a case report
Warshaw, Molly E., Baltz, Mathew J., Hollman, John H.

Mayo Clinic

Physiotherapy Theory and Practice | July 14, 2021 | Volume: 38 | Issue: 13 | Pages: 3180-3186

10.1080/09593985.2021.1946874 | PMID 34260331 Get It

Toward a Genetic Crystal Ball for Patients with Rotator Cuff Disease
Wijnen, André J. van , Abdel, Matthew P. , van Wijnen, Andre J , Abdel, Matthew P

Mayo Clinic

Journal of Bone and Joint Surgery | July 14, 2021 | Volume: 103 | Issue: 14 | Pages: e55

10.2106/jbjs.21.00434 | PMID 34260443 Get It